Bristol-Myers Squibb has dropped its option to buy single-asset cancer biotech F-star Alpha.

Takeda Pharmaceutical has teamed up with Harrington Discovery Institute to support research into treatments for rare diseases.

Struggling Teva bid farewell to longtime CFO Eyal Desheh, Immune Pharma's CEO Teper departed and Rgenix tapped ex-Novartis oncology scientist as CMO.

In this week's EuroBiotech Report, AstraZeneca’s late, over-budget HQ nears completion, Barcelona sweetens offer for EMA, argenx files for IPO and more.

Rgenix has named ex-Novartis staffer Roger Waltzman, M.D., as its chief medical officer.

Shares in U.K. biotech Synairgen were pummeled today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412.

Back in 2014, Roche spent $725 million upfront on California’s Seragon, but three years down the line, it has now canned work on its leading drug, ARN-810.

The Spanish government has ratcheted up the pressure on the European Council to make a quick decision on the new home of the region’s drug regulator.

The U.K.'s main pharma R&D lobby group has hit the national front pages today over threats the industry could start to leave the country.